WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Treat blood cancer
Disease control Not yet recruitingThis study tests the safety and effectiveness of combining two drugs, mosunetuzumab and pirtobrutinib, in 25 adults with Waldenstrom macroglobulinemia that has returned or not responded to prior treatment. Participants must have had at least one prior therapy, including a BTK inh…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in about 215 adults with B-cell cancers like lymphoma that have come back or not responded to prior treatment. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to find the safest …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New pill combo shows promise for rare blood cancer
Disease control Not yet recruitingThis study tests a combination of two oral medications, zanubrutinib and BGB-11417, in people with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combo can shrink or control the cancer better than current options. A…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo aims to fight rare blood cancer
Disease control Not yet recruitingThis study tests a new combination of three drugs (nemtabrutinib, bortezomib, and rituximab) in people newly diagnosed with Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to see how well the treatment shrinks or controls the cancer. About 19 adults will take pa…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC